|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Investments available for sale | ||||||||||||||||||||
| Fixed maturities | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Total investments available for sale | ||||||||||||||||||||
| Other invested assets | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Deferred policy acquisition costs | ||||||||||||||||||||
| Property and equipment (at cost, less accumulated depreciation of $74,054 in 2024 and $71,168 in 2023) | ||||||||||||||||||||
| Property, equipment and software (at cost, less accumulated depreciation of $73,197 in 2026 and $71,466 in 2025) | ||||||||||||||||||||
| Prepaid federal income tax | ||||||||||||||||||||
| Goodwill and acquired intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Reserve for losses and LAE | ||||||||||||||||||||
| Unearned premium reserve | ||||||||||||||||||||
| Net deferred tax liability | ||||||||||||||||||||
| Senior Notes due 2029, net | ||||||||||||||||||||
| Credit facility borrowings, net | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ Equity | ||||||||||||||||||||
| Common shares, $0.015 par value: Authorized - 233,333; issued and outstanding - 92,153 shares in 2026 and 95,456 shares in 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Common shares, issued (in shares) | ||||||||||||||||||||
| Common shares, authorized (in shares) |
Loading...
